无创评分预测肝脂肪变性的优势与不足

肝脏 ›› 2024, Vol. 29 ›› Issue (3): 260-262.

无创评分预测肝脂肪变性的优势与不足

李雨蓉, 钟昌明, 王杰

100191 北京大学基础医学院病原生物学系暨北京大学感染病研究中心

收稿日期:2024-03-02 出版日期:2024-03-31 发布日期:2024-05-16
通讯作者: 王杰,Email: wangjie2015@hsc.pku.edu.cn

Received:2024-03-02 Online:2024-03-31 Published:2024-05-16

摘要/Abstract

摘要： 非酒精性脂肪性肝病(NAFLD)全球负担加重提示了全民筛查和早期诊断的重要性。相比于影像学检查和肝组织活检,无创的肝脂肪变性评分为肝脂肪变性的预测提供了更加安全、简便和经济的方法。肝脂肪变性评分有助于减少低风险人群不必要的转诊,提高医疗保健的效率,且更适合NAFLD的流行病学研究。本文概述了NAFLD的检查手段和诊断标准,常见的肝脂肪变性评分,以及肝脂肪变性评分的优势、局限性及注意事项。

关键词: 肝脂肪变性, 非酒精性脂肪性肝病, 肝脂肪变性评分, 影像学检查, 肝组织活检

李雨蓉, 钟昌明, 王杰. 无创评分预测肝脂肪变性的优势与不足[J]. 肝脏, 2024, 29(3): 260-262.

参考文献

[1] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会,范建高,等. 非酒精性脂肪性肝病防治指南(2018更新版)[J]. 中华肝脏病杂志, 2018, 26(3): 195-203.
[2] Ko E, Yoon EL, Jun DW. Risk factors in nonalcoholic fatty liver disease[J]. Clin Mol Hepatol, 2023, 29(Suppl): S79-S85.
[3] Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement[J]. J Hepatol, 2020, 73(1): 202-209.
[4] Teng ML, Ng CH, Huang DQ, et al. Global incidence and prevalence of nonalcoholic fatty liver disease[J]. Clin Mol Hepatol, 2023, 29(Suppl): S32-S42.
[5] Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease[J]. Hepatology, 2005, 41(6): 1313-1321.
[6] 张馨元, 刘宇, 王文玲, 等. 非酒精性脂肪性肝病的诊断与评估[J]. 临床肝胆病杂志, 2023, 39(8): 1780-1788.
[7] Kinner S, Reeder SB, Yokoo T. Quantitative imaging biomarkers of NAFLD[J]. Dig Dis Sci, 2016, 61(5): 1337-1347.
[8] Younossi ZM, Marchesini G, Pinto-Cortez H, et al. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: implications for liver transplantation[J]. Transplantation, 2019; 103(1): 22-27.
[9] Reinshagen M, Kabisch S, Pfeiffer AFH, et al. Liver fat scores for noninvasive diagnosis and monitoring of nonalcoholic fatty liver disease in epidemiological and clinical studies[J]. J Clin Transl Hepatol, 2023, 11(5): 1212-1227.
[10] Congly SE, Shaheen AA, Swain MG. Modelling the cost effectiveness of non-alcoholic fatty liver disease risk stratification strategies in the community setting[J]. PLoS One, 2021, 16(5): e0251741.
[11] Lee JH, Kim D, Kim HJ, et al. Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver disease[J]. Dig Liver Dis, 2010, 42(7): 503-508.
[12] Han AL. Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease[J]. Diabetol Metab Syndr, 2022, 14(1): 44.
[13] McHenry S, Park Y, Browning JD, et al. Dallas steatosis index identifies patients with nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol, 2020, 18(9): 2073-2080.e7.
[14] Adams LA, Schulte PJ, Allen AM. Use of noninvasive scores to predict hepatic steatosis: Flaws and caveats[J]. Hepatology, 2023, 78(4): 1029-1031.
[15] Cuthbertson DJ, Weickert MO, Lythgoe D, et al. External validation of the fatty liver index and lipid accumulation product indices, using 1H-magnetic resonance spectroscopy, to identify hepatic steatosis in healthy controls and obese, insulin-resistant individuals[J]. Eur J Endocrinol, 2014, 171(5): 561-569.
[16] Taghdir M, Salehi A, Parastouei K, et al. Relationship between diet quality and nonalcoholic fatty liver disease predictor indices in Iranian patients with metabolic syndrome: A cross-sectional study[J]. Food Sci Nutr, 2023, 11(10): 6133-6139.
[17] Balkau B, Lange C, Vol S, et al. Nine-year incident diabetes is predicted by fatty liver indices: the French D.E.S.I.R. study[J]. BMC Gastroenterol, 2010, 10: 56.
[18] Nelson SM, Hoskins JD, Lisanti C, et al. Ultrasound fatty liver indicator: A simple tool for differentiating steatosis from nonalcoholic steatohepatitis: Validity in the average obese population[J]. J Ultrasound Med, 2020, 39(4): 749-759.